Goldman Sachs Lowers Estimates on Illumina
October 10, 2011
Goldman Sachs Lowers Estimates on Illumina
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Analysts, Investors 'Troubled' as Affymetrix's Preliminary Q3 Revenues Miss Estimates
October 9, 2012 / BioArray News - Next Round of GWAS a 'Wait-and-See Situation,' Says Illumina CEO
June 14, 2011 / BioArray News - Aiming at '$12B Opportunity,' Illumina to Expand Sales Presence, Invest in Reproductive Health
May 14, 2013 / BioArray News - GenomeWeb Feature: New Techniques Driving Research into Epigenetic Changes in Cancer
April 16, 2013 / GenomeWeb Daily News - Survey Offers 'Cautious Array Forecast' for Illumina as Sequencing, Affymetrix Products Gain Ground
April 16, 2013 / BioArray News